slides · global inventory
Development
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,188
Current window 8,881-8,910
Pages 373
Rows per page 30
Beat
8,881-8,910 of 11,188
16
Waterfall plot shows individual patient responses; table compares efficacy metrics against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
17
The slide uses a before-after-framing approach to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
18
The slide uses a swimmer plot to visualize individual patient treatment duration and response status.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
19
The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
20
Swimmer plot showing individual patient treatment duration and response status (NE, PD, PR, SD).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
21
The diagram uses a flow-chart structure to categorize patient outcomes (off treatment vs on treatment) and further breaks down the 'on treatment' group into SDs and PRs with specific progression delay metrics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
22
The chart displays adverse events occurring in >=10% of patients (n=15).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
23
CoC = Cost of Care (or standard of care context); FIH = First-in-Human; PTS = Probability of Technical Success; CDP = Clinical Development Plan.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
26
The slide uses two tables to demonstrate competitive advantage in potency and pharmacokinetics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
27
The diagram shows the signaling pathway with specific drug targets highlighted.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
28
The slide compares tumor volume reduction across two different CDX models (WiDr and RKO) using various treatment regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
29
Includes waterfall plot and swimmer plot for clinical trial results.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
30
Data cut 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
15
The slide uses a waterfall chart to explain sales growth and highlights adjusted EBITA and margin improvements.Essity | Results Presentation Deck | 25 slides · Essity
Conference presentation Investor relations Beat · Development1 hit
07
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
08
The slide uses a hub-and-spoke style diagram to show how different technical capabilities feed into and are informed by precision medicine.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
Includes a pie chart for TAM breakdown and a map visualization of regional market positions.Flutter | Investor Presentation Deck | 28 slides · Flutter Entertainment
Conference presentation Investor relations Beat · Agitate (Make it worse)1 hit
08
The slide uses a custom matrix/grid to map brands to shared platform capabilities.Flutter | Investor Presentation Deck | 28 slides · Flutter Entertainment
Conference presentation Investor relations Beat · Agitate (Make it worse)1 hit
04
The slide uses a three-column layout to highlight key value propositions of the Olvi-Vec technology.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
05
The slide uses a Gantt-style visualization to show clinical trial stages for multiple drug candidates.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
06
Uses a process diagram to illustrate the transition from cold to hot tumor states via viral infection.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The central diagram shows a biological mechanism comparing 'Absence of Effector T Cells' (Platinum resistant) vs 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
The slide uses a timeline to establish market maturity and investor confidence.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
05
The slide uses a 2D matrix/positioning map to illustrate market positioning based on ECG technology lead count vs. clinical diagnostic capabilities.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · Agitate1 hit
06
The slide uses a bubble chart representation to visually compare market sizes.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · Agitate1 hit
12
AA = Advanced Adenoma; CRC = Colorectal Cancer. Data source cited at bottom.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit